Abstract | BACKGROUND:
Cognitive impairment is a core feature of bipolar disorder, with a prevalence of about 64.4% during episodes and 57.1% in euthymia. Recent evidences suggest that cognitive deficits in BD may follow immune dysfunction and elevated levels of inflammatory cytokines have been reported during periods of depression, mania and euthymia, suggesting the presence of a chronic, low-grade inflammatory state. The aim of the study is to investigate if immune/inflammatory markers and especially chemokines associate to cognitive performances. METHODS: RESULTS: Higher levels of IL-1β, IL-6, CCL2, CCL4, CCL5, CXCL10, and bFGF are associated with the likelihood of having a poor cognitive performance. LIMITATIONS: Limitation include the lack of a group of healthy controls and the lack of information regarding previous psychopharmacological treatments, alcohol and tobacco use. CONCLUSIONS: Our results confirm the importance of chemokines in bipolar disorder and suggest that inflammatory markers suggestive of a low-grade inflammatory state could contribute to the neurocognitive deficits observed in depressed patients.
|
Authors | Sara Poletti, Mario Gennaio Mazza, Federico Calesella, Benedetta Vai, Cristina Lorenzi, Elena Manfredi, Cristina Colombo, Raffaella Zanardi, Francesco Benedetti |
Journal | Journal of psychiatric research
(J Psychiatr Res)
Vol. 140
Pg. 110-116
(08 2021)
ISSN: 1879-1379 [Electronic] England |
PMID | 34107379
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2021 Elsevier Ltd. All rights reserved. |
Topics |
- Bipolar Disorder
(complications, epidemiology)
- Cognition
- Cognition Disorders
- Cognitive Dysfunction
(epidemiology, etiology)
- Humans
- Neuropsychological Tests
|